

## Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel, April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May.

### British Society for Rheumatology Annual Conference - April 24-26, 2023

**Date:** April 24, 2023  
**Time:** 9:45am BST  
**Venue:** Manchester Central Convention Complex, Manchester, UK and virtual  
**Format:** Oral presentation: *CCL24 Serum Concentration Predicts Both Vascular and Fibrotic Complications in Systemic Sclerosis: Rationale for a Biological Target Driven, Basket Trial Across Disease Subsets*  
**Presenter:** Professor Enrico De Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal Diseases, University of Leeds, UK  
**Information:** <https://www.rheumatology.org.uk/events-learning/conferences/annual-conference>

### EASL Monothematic Conference on Biliary Fibrosis 2023 - May 12-13, 2023

**Date:** May 12, 2023  
**Time:** 17:20-17:50 CEST  
**Venue:** Grand Hotel Baglioni, Florence, Italy  
**Format:** Poster presentation: *Patient proteomic data and mouse model reinforce the proinflammatory role of CCL24 in cholestatic disease*  
**Session:** ePoster session 3 and break  
**Presenter:** Matt Frankel, MD, Chief Medical Officer, Chemomab  
**Information:** <https://easl.eu/event/biliary-fibrosis-23/>

In addition, Chemomab's corporate development team will be in Boston June 5-8, 2023, participating in the **BIO International Convention's One-on-One Partnering™** event. Registered attendees can click [here](#) to log in and schedule a meeting with Chemomab.

### About Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit [chemomab.com](https://chemomab.com).

### Contacts:

<b>Investors:</b>	<b>Investors &amp; Media:</b>
Irina Koffler	Barbara Lindheim
LifeSci Advisors, LLC	Chemomab Therapeutics
Phone: +1 (917) 734-7387	Consulting Vice President, Investor & Public Relations
<a href="mailto:ir@chemomab.com">ir@chemomab.com</a>	Strategic Communications
	<a href="mailto:barbara.lindheim@chemomab.com">barbara.lindheim@chemomab.com</a>

SOURCE Chemomab Therapeutics, Ltd.

---